meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced - esophageal cancer (mEC)
mEC - (neo)adjuvant (NA)
1
mEC - 1st line (L1)
1
mEC - 2nd line (L2)
3
gastric or gastroesophageal junction cancer (GC)
immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
PD-L1 > 10%
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
mEC - 1st line (L1)
metastatic/advanced - esophageal cancer (mEC)
mEC - 1st line (L1)
versus placebo plus SoC
pembrolizumab plus SoC vs. placebo plus SoC
1
certainty unassessable
statistically conclusive
-25%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open